Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability: 2018-2025

Historic Non-Current Deferred Tax Liability for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $230.8 million.

  • Takeda Pharmaceutical's Non-Current Deferred Tax Liability fell 69.99% to $230.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $230.4 million, marking a year-over-year decrease of 69.99%. This contributed to the annual value of $230.8 million for FY2025, which is 70.75% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Non-Current Deferred Tax Liability of $230.8 million as of FY2025, which was down 70.75% from $788.9 million recorded in FY2024.
  • In the past 5 years, Takeda Pharmaceutical's Non-Current Deferred Tax Liability ranged from a high of $5.1 billion in FY2021 and a low of $230.8 million during FY2025.
  • Its 3-year average for Non-Current Deferred Tax Liability is $1.0 billion, with a median of $788.9 million in 2024.
  • Data for Takeda Pharmaceutical's Non-Current Deferred Tax Liability shows a maximum YoY slumped of 70.75% (in 2025) over the last 5 years.
  • Yearly analysis of 5 years shows Takeda Pharmaceutical's Non-Current Deferred Tax Liability stood at $5.1 billion in 2021, then fell by 21.46% to $4.0 billion in 2022, then plummeted by 50.19% to $2.0 billion in 2023, then plummeted by 60.62% to $788.9 million in 2024, then crashed by 70.75% to $230.8 million in 2025.